As part of the planned merger between Fresenius Kabi and Unizell Medicare GmbH, the daughter company of the health group Fresenius is seeking to increase cooperation between the two companies. The company is in contact with the Federal Cartel Office in regard to this. The business relationship is supposed to extend to the product areas clinical nutrition and infusion therapy as well as intravenously administered medications.
According to reports by the publisher MTD-Verlag, they are not planning to increase their stake or even take over the trader Unizell Medicare. Fresenius Kabi has been a minority shareholder of the trader from Ratekau/Kreuzkamp in Schleswig-Holstein since 2008.
Fresenius Kabi specializes in generic medications to be administered intravenously, as well as infusion therapies and clinical nutrition. A turnover of 3.964 billion Euro generated by Fresenius Kabi represents a quarter of the Fresenius‘ group turnover in 2011. Unizell Medicare’s portfolio comprises products for incontinence and nutrition as well as cleaning & hygiene.
[ilink url=“http://www.mtd.de/cms/“] source: MTD-Verlag[/ilink]